Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Readability of COVID-19 vaccine information for the general public
Luke S. Bothun, Scott E. Feeder, Gregory A. Poland

Mayo Vaccine Research Group, Mayo Clinic, Rochester, MN, USA

Abstract

Background: More than 130 million individuals in the United States have now received at least one dose of a COVID-19 vaccine. Currently, all adults in the United States now have access to one of three COVID-19 vaccines. As part of the vaccination procedure, Emergency Use Authorization (EUA) fact sheets, which contain information regarding the vaccine, are provided. The purpose of this study was to analyze the ease of reading (i.e., readability) of the EUA-approved fact sheets for the vaccines currently available in the United States, the V-Safe adverse event survey script, and the Centers for Disease Control and Prevention (CDC) website information on COVID-19 vaccines designed for the general public in the United States.

Methods: We acquired the Pfizer, Moderna, and Janssen EUA fact sheets, as well as the V-Safe survey script and the CDC website information regarding COVID-19 vaccines. These documents were analyzed for their complexity regarding the following readability factors: average length of paragraphs, sentences, and words; font size and style; use of passive voice; the Gunning-Fog index; the Flesch Reading Ease index; and the Flesch-Kincaid Grade Level index.

Results: Only the V-Safe adverse-event survey script met readability standards for adequate comprehension. The mean readability scores of the EUA fact sheets and the CDC website were as follows: Flesch Reading Ease score (44.35 avg); Flesch-Kincaid Grade Level (10.48 avg); and Gunning-Fog index (11.8 avg). These scores indicate that at least a 10th-grade level education would be required to understand these reading materials.

Conclusion: The average person in the United States would have difficulty understanding the information provided in the EUA fact sheets and CDC COVID-19 vaccine website documents; however, the V-Safe survey was written at an adequate reading level. To ensure that the general public fully understands information regarding COVID-19 vaccines, greater care and effort should be given to the development of simplified information material.

1. Introduction

The 2019 coronavirus disease (COVID-19) has resulted in a global pandemic and the subsequent development of vaccines. Vaccine recipients are encouraged to read several vaccine information documents before they receive a vaccine, including reviewing the Centers for Disease Control and Prevention (CDC) website on COVID-19 vaccines and the vaccine-specific emergency-use authorization (EUA) fact sheet for the Pfizer, Moderna, or Janssen vaccine they are receiving. Subjects are also encouraged to sign up for an adverse-event tracking survey called V-Safe after they receive their vaccination. In addition, the CDC website on COVID-19 and the EUA fact sheets contain basic vaccine information for the general public, including potential benefits, risks, side effects, and necessary precautions. The purpose of this study was to analyze the readability of the EUA fact sheets, the CDC website on COVID-19 vaccine questions, and the V-Safe adverse-event survey script for vaccines in the United States to determine if they meet the guidelines for adequate public readability.

Vaccine recipients should fully comprehend vaccine information reading material in order to weight the risks and benefits of vaccination and to adequately understand the possible risks and benefits of receiving the vaccine. Because these documents are the primary method of communicating vaccine information to the public, the readability of these materials is critical. Several readability factors may hamper understanding of reading material, including the subject’s education level and the readability of the document. Font size, layout, charts, pictures, vocabulary, and word length also influence readability [1].

https://doi.org/10.1016/j.vaccine.2022.04.096
0264-410X/© 2022 Elsevier Ltd. All rights reserved.
Determining the readability of a document is necessary to make sure that the text is written at an adequate comprehension level for the general public with differing reading skills [2]. A National Work Group on Literacy and Health study demonstrated that approximately 25% of U.S. citizens have very low-level reading skills and are unable to comprehend a bus schedule or medication and cleaning-product labels [3]. However, it is vital that all individuals be able to understand the necessary information before receiving a vaccine. The National Adult Literacy Agency suggests that reading materials for the general population should have a 7th-grade readability level, which is the average reading level for adults in the United States [4]. Many experts advise using plain wording, active voice, short sentences, and present tense to achieve this grade level of reading [5].

### 2. Methods

We acquired the following vaccine information documents: vaccine-specific COVID-19 vaccine EUA fact sheets, which are given to COVID-19- vaccine recipients in the United States, from Pfizer, Moderna, and Janssen; the full V-Safe adverse-event survey script; and the text related to COVID-19 vaccines found on the CDC website for members of the general public (specifically, the following links: Questions and Answers; Does it Work?; Is it safe?; Are there side effects?; and What if I am pregnant or breastfeeding?) [6]. These documents were selected and reviewed because they were accessible to the public. Although the length of the V-Safe script varies based on the symptoms being reported, we reviewed the entire script because it is possible that some people could view the script in full.

To increase accuracy and reduce bias, two study authors independently analyzed the readability and formatting metrics of each document using Microsoft Word readability tools and calculators. We used several formatting metrics, including total length, sentence length, font size and style, and percentage of passive sentences, in addition to three standard readability formulas to analyze the reading difficulty of each document. The Flesch Reading Ease score is a widely used and trusted readability formula that predicts ease of reading on a scale from 1 to 100, with higher scores indicating easier readability and 70 being the level of an average U.S. reader [5].

The Flesch-Kincaid Grade Level score is a readability index that determines the ease of readability on a scale from 1 to 12. This score corresponds to the education-grade level necessary to comprehend a passage, [5] but scores below 1 or above 12 are obtainable. For comprehension within the U.S. general public, a 7th-grade reading level is advised, but an 8th-grade reading level is often acceptable and lower levels of 5th-grade or 6th-grade are necessary when targeting audiences with low levels of literacy [7]. Table 1 compares the Flesch-Kincaid Grade Level score and Flesch Reading Ease score.

The Gunning-Fog index is a readability index that scores text from 1 to 20. Scores are derived from the number of complex or polysyllabic words in a sentence and the number of sentences in a roughly 100-word passage. A more cohesive score is obtained by averaging the Gunning-Fog index score for three random 100-word passages throughout a document. An index of 7 is necessary to achieve near-universal comprehension in the United States [8]. Our scores ranged from 6 to 17 and corresponded to 6 = 6th grade to 17 = college graduate.

### 3. Results

We reviewed the COVID-19 vaccine fact sheets for the Pfizer, Moderna, and Janssen vaccines available under EUA in the US, the complete V-Safe adverse event survey script, and the CDC general public website on information about COVID-19 vaccines. No significant differences were detected in the Microsoft scoring metrics between the two independent study authors who analyzed readability.

Document length ranged from 5 to 18 pages (8.25 avg). The number of words (including headers) ranged from 1,662 to 5,564 (3,086.8 avg). Average words per page ranged from 175.9 to 334.2 (294.8 avg), and average words per paragraph ranged from 7.0 to 25.1 (17.76 avg). Font size ranged from 11 to 16 points. All documents used sans serif fonts. The average word length ranged from 4.9 to 5.4 characters (5.18 avg). Average sentence length ranged from 9.8 to 18.7 words (14.4 avg). See Table 2.

The percent of passive sentences ranged from 0.2% to 21.1% (15.04% avg). The Flesch Reading Ease Score ranged from 40.9 to 66.8 (48.84 avg). The Flesch-Kincaid Grade Level ranged from 6.3 to 11.6 (9.76 avg). The Gunning-Fog Score ranged from 8.03 to 12.43 (11.19 avg). See Table 3.

### 4. Discussion

This study focuses on the vaccine information readability for the COVID-19 vaccines currently distributed in the United States. The importance of readability regarding public health information has been articulated by others relating to COVID-19 [9–11]. Our analysis found that only the V-Safe adverse-response survey script met most of the recommended readability levels for average vaccine recipients. However, the V-Safe study did not achieve an adequate Gunning-Fog index score, indicating that readability could be further improved by using sentences that are less complex. None of the other information sources we reviewed met current readability standards.

Readability studies demonstrate that the general public in the United States is less likely to understand long and complex documents, [12] and that health information documents should be shorter than 15 pages [13]. The vaccine information documents in this study had an acceptable average of 8.25 page length, but the range extended to 18 pages. Note that we excluded the V-Safe script as an outlier with 28 pages. High word density, or too many words in a sentence, also raises the difficulty level of a text; therefore, it is advised that sentences are a maximum of 12 – 17

### Table 1

| Type of Magazine | Estimated School Grade Completed | Estimated Percent of US Adults |
|------------------|----------------------------------|-------------------------------|
| Comics           | 4th grade                        | 93                            |
| Pulp Fiction     | 5th grade                        | 91                            |
| Slick Fiction    | 6th grade                        | 88                            |
| Digests          | 7th or 8th grade                 | 83                            |
| Quality          | Some high school                 | 54                            |
| Academic         | High school to college           | 33                            |
| Scientific       | College                          | 4.5                            |

3467
words long [14]. Although the average sentence length (14.4 words) in our study was acceptable, the range extended to 18.7 words.

Font style and size also play roles in analyzing the readability of a text. Sans serif fonts (i.e., Arial and Calibri) are easier to read than serif fonts (i.e., Times New Roman). Also, smaller fonts such as size 12 are harder to read than larger fonts such as size 14 [15]. All documents used an appropriate font style, but the size 12 font found in every document was too small. Many passive-voice sentences, or sentences with the subject receiving the action of the verb, also decrease readability [5]. The average percentage of passive-voice sentences in our study was fairly low, but the range extended up to 21%.

Because nearly half of adults in the United States read at a 7th-grade level, [7] vaccine information materials provided for the currently COVID-19 vaccines are too difficult to understand for many adult readers. In addition to simplified readability, instructional graphics should be used to increase comprehension levels. Other multimedia, including pictures, videos, colors, slideshows, and charts, were used on the CDC website and the V-Safe survey but not in the EUA vaccine fact sheets and may increase comprehension. In addition, the responsive nature of the V-Safe survey exposes the individual to very small amounts of text at any one time, making it easier to read and comprehend. Further study is required of cultural and educational barriers to determine the most useful methods of patient education. Personal discussion between vaccine recipients and healthcare professionals may be another useful methods of patient education. Personal discussion between patients and healthcare professionals, may improve the general public's understanding of vaccine effects and personal discussion between patients and healthcare professionals, may improve the general public's understanding of COVID-19 vaccines. This study also uses standardized, reliable, and widely used metrics to assess readability.

Disclosures

Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice on vaccine development to AliZtech; Atria; AstraZeneca UK Limited; Contec, Inc.; 3D Communications; Eli Lilly and Company; Emergent Biosolutions; Exelixis, Inc.; ExpertConnect; Genevant Sciences, Inc.; GlaxoSmithKline; Janssen Global Services, LLC; Janssen Research & Development, LLC; Medicago USA; Medscape, LLC; Merck & Co. Inc.; Moderna; Regeneron Pharmaceuticals, Inc.; Sanofi Pasteur SA; Syneos Health and Vyriad. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.

Table 2
Online COVID-19 Vaccine Document Statistics.

| Document                          | Total Pages | Total Paragraphs | Total Words | Words/Page | Font Style | Font Size | Word Length | Sentence Length |
|----------------------------------|-------------|------------------|-------------|------------|------------|-----------|-------------|----------------|
| V-Safe Survey Script             | 28          | 624              | 4,924       | 7.0        | Calibri    | 11        | 4.9         | 9.8            |
| Pfizer EUA Fact Sheet            | 5           | 101              | 1,671       | 16.5       | Arial      | 12        | 5.4         | 14.1           |
| Moderna EUA Fact Sheet           | 5           | 83               | 1,662       | 20.0       | Arial      | 12        | 5.2         | 15             |
| Janssen EUA Fact Sheet           | 5           | 50               | 1,613       | 20.2       | Arial      | 12        | 5.3         | 14.4           |
| CDC COVID-19 Vaccine Website     | 18          | 222              | 5,564       | 25.1       | Arial      | 14-16     | 5.1         | 18.7           |
| Recommended                      | <15         | None             | None        | None       | Arial/Calibri | ≥14      | None         | 12-17          |

Table 3
Online COVID-19 Vaccine Document Readability Scores.

| Document                          | % Passive | Flesch Reading Ease | Flesch-Kincaid Grade Level | Gunning-Fog Index |
|----------------------------------|-----------|--------------------|---------------------------|------------------|
| V-Safe Survey Script             | 0.2%      | 66.8               | 6.3                       | 8.77             |
| Pfizer EUA Fact Sheet            | 16.9%     | 40.9               | 10.7                      | 10.48            |
| Moderna EUA Fact Sheet           | 18.7%     | 46.2               | 10.2                      | 10.78            |
| Janssen EUA Fact Sheet           | 18.3%     | 46.1               | 10                        | 10.77            |
| CDC COVID-19 Vaccine Website     | 21.1%     | 44.2               | 11.6                      | 15.17            |
| Recommended                      | 0%        | ≥70                | ≤7                        | ≤7               |
Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Shen Y. On Improving Text Readability by Creating a Personal Writing Style. English Language Teaching 2017;10(3):95–100.
[2] Chen X, Meurers D. Word Frequency and Readability: Predicting the Text-Level Readability with a Lexical-Level Attribute. J Res Reading 2018;41(3):486–510.
[3] Weiss BD. Communicating with patients who have limited literacy skills: Report of the national work group on literacy and health. J Fam Pract 1998;46(2):168–76.
[4] University of California Santa Cruz Office of Research. Informed Consent: Readability/Literacy Level. https://officeofresearch.ucsc.edu/compliance/services/irb22_consent_readability.html.
[5] DuBay WH. The Principles of Readability. Costa Mesa, CA: Impact Information; 2004.
[6] Centers for Disease Control and Prevention. COVID-19 vaccine fact sheet. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.
[7] Paasche-Orlow MK, Taylor HA, Brancati FL. Readability Standards for Informed-Consent Forms as Compared with Actual Readability. N Engl J Med 2003;348(8):721–6.
[8] Seeley J. Oxford Guide to Effective Writing and Speaking: How to Communicate Clearly. OUP Oxford; 2013.
[9] Emanuel EJ, Boyle CW. Assessment of Length and Readability of Informed Consent Documents for COVID-19 Vaccine Trials. JAMANetw Open 2021;4(4):e2110843.